Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (Symbol: BEAT) is a cutting-edge medical technology company that focuses on developing and commercializing high-resolution ambulatory Electrocardiogram (ECG) solutions. These solutions are designed to detect and monitor cardiac diseases outside traditional healthcare settings, providing critical diagnostic capabilities in a more accessible manner.
HeartBeam's flagship product is an innovative, credit card-sized ECG device that is diagnostically equivalent to a cardiologist reading a patient's 12-lead ECG and examining the patient. This compact device integrates seamlessly with a cloud-based diagnostic expert system, offering a comprehensive and user-friendly solution for cardiac monitoring.
Notably, studies designed by Harvard Medical School faculty have demonstrated that HeartBeam's technology performs on par with, or better than, world-class cardiologists in diagnosing heart attacks. The system features personalized diagnostic thresholds and unique ECG markers that help pinpoint the location of a heart attack on a 3D heart model, enhancing the accuracy and depth of diagnostic information provided to healthcare professionals.
One of the key components of HeartBeam's technology is the iCardiologist application, which uses artificial intelligence and machine learning to continually improve its diagnostic accuracy and predictive capabilities. This application aids cardiologists by providing detailed patient analysis, thereby supporting more informed and timely medical decisions.
HeartBeam has developed a proprietary and patented Vector Electrocardiography (VECG) technology platform, which is the cornerstone of its high-resolution ECG solutions. The company has validated this platform and is in the process of seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.
With its innovative approach and proven technology, HeartBeam is poised to make significant strides in the field of cardiac care, offering practical solutions that can be utilized outside traditional healthcare environments, thereby broadening access to critical diagnostic tools and improving patient outcomes.
Latest News: Source: HeartBeam, Inc.
- ------
- ------
- ------
HeartBeam, Inc. (NASDAQ: BEAT) announced its acquisition of LIVMOR’s assets, including the FDA-cleared Halo+™ Atrial Fibrillation Detection System, enhancing its remote monitoring capabilities. The partnership with Evolve Manufacturing aims to develop the HeartBeam AIMIGo 12-Lead electrocardiogram device, with initial market testing slated for Q4 2023 post-FDA clearance. The company received European patents protecting its technology, facilitating expansion. Financial results show a net loss of $3.7 million for Q4 2022, up from $2.1 million a year prior, with cash reserves at $3.6 million. Management projects further advancements in FDA submissions in 2023.
HeartBeam, Inc. (NASDAQ: BEAT) has acquired substantially all assets of LIVMOR, a digital health solutions company, enhancing its capabilities in remote cardiac monitoring. This acquisition includes the FDA-cleared Halo+™ Atrial Fibrillation Detection System, the first prescription wearable for continuous monitoring of cardiac rhythms. Founded in 2016, LIVMOR's technology has been deployed in the VA Healthcare System in Dallas, Texas. The strategic move is expected to integrate LIVMOR's cloud-based software with HeartBeam's existing solutions, potentially improving patient outcomes and reducing healthcare costs. Financial terms remain undisclosed.
HeartBeam, Inc. (NASDAQ: BEAT) announced a senior leadership change with
HeartBeam, Inc. (NASDAQ: BEAT), a company specializing in cardiac technology, will hold a conference call on Thursday, March 16, 2023, at 4:30 p.m. Eastern time to discuss its fourth quarter and full fiscal year results for 2022. The call will cover recent announcements, ongoing initiatives, and key milestones for 2023. Attendees can access the call via a webcast or by dial-in options. A replay will be available until June 16, 2023. HeartBeam has developed a unique 3D-vector ECG platform for heart attack detection.
HeartBeam, Inc. (NASDAQ: BEAT) has appointed Robert Eno as President, a newly created role aimed at enhancing the company's strategic and operational capabilities. Eno brings over 28 years of experience in developing markets for innovative medical technologies. He will be instrumental in the strategic direction and commercialization of HeartBeam's AIMI™ and AIMIGo™ platforms, which are designed for remote heart attack detection. HeartBeam, known for its unique 3D-vector ECG platform, seeks to establish itself as a leader in ambulatory cardiology.
HeartBeam, Inc. (NASDAQ: BEAT) announced the issuance of a patent for its AIMIGo™ device, which provides 12-lead ECG capability, enhancing heart attack detection. This patent, granted by the European Patent Office, covers several European countries, validating HeartBeam's innovative technology. With over 11 million new cardiovascular disease cases annually in Europe, the AIMIGo device aims to allow patients to monitor their heart health outside medical settings. The innovation supports timely diagnosis and intervention for cardiac patients.
HeartBeam, Inc. (NASDAQ: BEAT) has announced significant advancements in their cardiac technology products, particularly the HeartBeam AIMIGo and HeartBeam AIMI systems, aimed at enhancing heart attack detection. The company anticipates regulatory approval for the HeartBeam AIMI system in Q1 2023 and plans to submit HeartBeam AIMIGo for FDA clearance soon. HeartBeam aims to transform patient care by providing remote heart attack detection with their innovative 12-lead 3D vector ECG technology. They have also strengthened their intellectual property with several new patents, positioning themselves for growth in the healthcare market.
HeartBeam, Inc. (NASDAQ: BEAT) has partnered with Evolve Manufacturing Technologies to manufacture the AIMIGo 3D vector electrocardiogram (VECG) device. This credit card-sized device facilitates remote heart attack detection and is expected to enter early market testing in Q2 2023, pending FDA clearance. The AIMIGo solution aims to enhance heart attack detection for patients outside medical settings, addressing a significant need as more than 18 million U.S. citizens suffer from coronary artery disease.
HeartBeam, Inc. (NASDAQ: BEAT) has received an allowed patent for a 12-lead ECG smartwatch designed to detect heart attacks and complex cardiac arrhythmias, according to a recent announcement. This innovative technology aims to disrupt the multi-billion dollar wearable device market, which is projected to reach
HeartBeam, Inc. (NASDAQ: BEAT) announced the submission of its HeartBeam AIMI™ platform for FDA clearance, enhancing its heart attack detection technology. The company also plans to submit the AIMIGo telehealth solution by Q4 2022. With two new patents granted, HeartBeam aims to expand its product pipeline to include smartwatch connectivity. Financially, the company reported a net loss of $3.6 million for Q3 2022, up from $1.2 million the previous year, with research and development expenses reaching $1.6 million. Cash reserves stood at $6.5 million as of September 30, 2022.
FAQ
What is the current stock price of Heartbeam (BEAT)?
What is the market cap of Heartbeam (BEAT)?
What does HeartBeam, Inc. do?
What is unique about HeartBeam's technology?
How does HeartBeam's iCardiologist application work?
What is VECG technology?
Has HeartBeam's technology been validated?
Is HeartBeam seeking FDA clearance?
What are the benefits of HeartBeam's ECG solutions?
Can HeartBeam's technology locate a heart attack?
How is HeartBeam improving cardiac care?
Where can I find the latest news on HeartBeam, Inc.?
